GLAUKOS Corp (GKOS)
Sector: Healthcare
Industry: Surgical & Medical Instruments & Apparatus
Country: United States
Exchange: NYSE
Market cap: $9.66B
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Latest financial period: June 30, 2026
Filed with the SEC: July 29, 2026
Estimated earnings date: November 4, 2026
Profit #1329 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 8.1% | 7.6% | 7.1% | 10.0% |
Growth #30 of 1484 companies
Payout #1117 of 1484 companies
Safety #741 of 1484 companies
Price #1355 of 1484 companies
